Literature DB >> 32450266

Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.

Yuchen Xia1, Haitao Guo2.   

Abstract

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with about 257 million individuals chronically infected. Current therapies can effectively control HBV replication and slow down disease progress, but cannot cure HBV infection. Upon infection, HBV establishes a pool of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. The cccDNA exists as a minichromosome and resists to antivirals, thus a therapeutic eradication of cccDNA from the infected cells remains unattainable. In this review, we summarize the state of knowledge on the mechanisms underlying cccDNA formation and regulation, and discuss the possible strategies that may contribute to the eradication of HBV through targeting cccDNA.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug target; HBV cccDNA minichromosome; HBV cure; Host-virus interaction; Transcriptional regulation; cccDNA eradication

Year:  2020        PMID: 32450266      PMCID: PMC7387223          DOI: 10.1016/j.antiviral.2020.104824

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  140 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

3.  In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase.

Authors:  Scott A Jones; Rajeev Boregowda; Thomas E Spratt; Jianming Hu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.

Authors:  Chiara Braconi; Nianyuan Huang; Tushar Patel
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

5.  SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations.

Authors:  Adriana Goncalves; Evren Karayel; Gillian I Rice; Keiryn L Bennett; Yanick J Crow; Giulio Superti-Furga; Tilmann Bürckstümmer
Journal:  Hum Mutat       Date:  2012-04-16       Impact factor: 4.878

6.  Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events.

Authors:  Birgit Rabe; Dieter Glebe; Michael Kann
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment.

Authors:  Alina Macovei; Catalina Petrareanu; Catalin Lazar; Paula Florian; Norica Branza-Nichita
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

8.  Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell.

Authors:  C T Bock; P Schranz; C H Schröder; H Zentgraf
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

9.  Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism.

Authors:  H Tang; A McLachlan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

Review 10.  HBV DNA Integration: Molecular Mechanisms and Clinical Implications.

Authors:  Thomas Tu; Magdalena A Budzinska; Nicholas A Shackel; Stephan Urban
Journal:  Viruses       Date:  2017-04-10       Impact factor: 5.048

View more
  24 in total

Review 1.  Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases.

Authors:  Ridhwaanah Jacobs; Prashika Singh; Tiffany Smith; Patrick Arbuthnot; Mohube Betty Maepa
Journal:  Gene Ther       Date:  2022-05-24       Impact factor: 5.250

2.  DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation.

Authors:  Yingshan Chen; Yongxuan Yao; Kaitao Zhao; Canyu Liu; Yifei Yuan; Hao Sun; Dan Huang; Yi Zheng; Yuan Zhou; Jizheng Chen; Yun Wang; Chunchen Wu; Bixiang Zhang; Yujuan Guan; Feng Li; Rongjuan Pei; Xinwen Chen
Journal:  J Virol       Date:  2022-06-07       Impact factor: 6.549

3.  SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters.

Authors:  Dai-Qing Wu; Qiu-Ying Ding; Na-Na Tao; Ming Tan; Yuan Zhang; Fan Li; Yu-Jiao Zhou; Mei-Ling Dong; Sheng-Tao Cheng; Fang Ren; Juan Chen; Ji-Hua Ren
Journal:  Front Microbiol       Date:  2022-05-19       Impact factor: 6.064

4.  Substituted Chromen-4-one Derivatives for Treating Hepatitis B Virus Infection.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-02-17       Impact factor: 4.345

5.  Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20.

Authors:  Daniela Stadler; Martin Kächele; Alisha N Jones; Julia Hess; Christian Urban; Jessica Schneider; Yuchen Xia; Andreas Oswald; Firat Nebioglu; Romina Bester; Felix Lasitschka; Marc Ringelhan; Chunkyu Ko; Wen-Min Chou; Arie Geerlof; Maarten A van de Klundert; Jochen M Wettengel; Peter Schirmacher; Mathias Heikenwälder; Sabrina Schreiner; Ralf Bartenschlager; Andreas Pichlmair; Michael Sattler; Kristian Unger; Ulrike Protzer
Journal:  EMBO Rep       Date:  2021-05-09       Impact factor: 8.807

6.  Novel Substituted 3,4-Dihydroquinazoline Derivatives for Treating Hepatitis B Virus Infection.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-06-04       Impact factor: 4.632

Review 7.  Recent Advances in Hepatitis B Treatment.

Authors:  Georgia-Myrto Prifti; Dimitrios Moianos; Erofili Giannakopoulou; Vasiliki Pardali; John E Tavis; Grigoris Zoidis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-01

8.  Cas9-targeted nanopore sequencing reveals epigenetic heterogeneity after de novo assembly of native full-length hepatitis B virus genomes.

Authors:  Chloe Goldsmith; Damien Cohen; Anaëlle Dubois; Maria Guadalupe Martinez; Kilian Petitjean; Anne Corlu; Barbara Testoni; Hector Hernandez-Vargas; Isabelle Chemin
Journal:  Microb Genom       Date:  2021-05

9.  Elevated NTCP expression by an iPSC-derived human hepatocyte maintenance medium enhances HBV infection in NTCP-reconstituted HepG2 cells.

Authors:  Xinlei Li; Zhaohui Xu; Bidisha Mitra; Minghang Wang; Haitao Guo; Zongdi Feng
Journal:  Cell Biosci       Date:  2021-07-05       Impact factor: 7.133

Review 10.  Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.

Authors:  Laura A Novotny; John Grayson Evans; Lishan Su; Haitao Guo; Eric G Meissner
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.